8-K: bioAffinity Technologies Reports 217% Sales Growth for CyPath Lung in Second Quarter 2024, Raises Full-Year Forecast

bioAffinity Technologies announced a 217% increase in second-quarter sales of its CyPath Lung test compared to the first quarter of 2024 and raised its full-year sales forecast by 85%.

Summary

• bioAffinity Technologies reported a significant 217% increase in sales of its CyPath Lung test in the second quarter of 2024 compared to the first quarter.
• The company has raised its full-year sales forecast for CyPath Lung by 85% due to the accelerating sales growth.
• The company now expects to exceed 880 CyPath Lung tests in 2024.
• Precision Pathology Laboratory Services (PPLS), a subsidiary of bioAffinity, is projected to generate between $9.2 and $9.6 million in revenue in 2024, including sales of CyPath Lung.
• Physicians ordered 168 CyPath Lung tests in the second quarter of 2024, compared to 53 in the first quarter and 12 in the fourth quarter of 2023.
• CyPath Lung has demonstrated 92% sensitivity and 87% specificity in detecting lung cancer in patients with pulmonary nodules 20 millimeters or less.
• The company is planning a broader market launch for CyPath Lung in the fourth quarter of 2024.
• The lung cancer diagnostics market is projected to reach $4.7 billion by 2030.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the significant sales growth, increased forecast, and positive clinical results for CyPath Lung. The company's strategic approach and market opportunity also contribute to the high sentiment.

Positives

• The company experienced a substantial 217% growth in CyPath Lung sales in the second quarter of 2024, indicating strong market acceptance.
• The 85% increase in the full-year sales forecast suggests confidence in continued growth.
• The number of CyPath Lung tests ordered by physicians has increased significantly, from 12 in Q4 2023 to 168 in Q2 2024.
• CyPath Lung has demonstrated high sensitivity (92%) and specificity (87%) in detecting lung cancer.
• The company is expanding its sales team and onboarding new physicians weekly.
• Private insurers have begun reimbursing for the test, which is billed at $1,900.
• The company is preparing for a broader market launch in the fourth quarter of 2024.

Risks

• The company's ability to continue to accelerate the commercialization of CyPath Lung and capitalize on the lung cancer diagnostics market is subject to various risks and uncertainties.
• The ability of CyPath Lung to provide the anticipated benefits to patients and physicians is not guaranteed.
• The company's future performance is subject to factors discussed in their Annual Report on Form 10-K and subsequent filings with the SEC.

Future Outlook

The company anticipates continued growth in CyPath Lung sales, with a broader market launch planned for the fourth quarter of 2024 and expects to exceed 880 tests in 2024. The company also projects PPLS to generate between $9.2 and $9.6 million in revenue in 2024.

Management Comments

• Maria Zannes, President and CEO of bioAffinity Technologies, stated that the company strategically focused its marketing efforts on Texas as they launched CyPath Lung.
• Maria Zannes also noted that the strategic decision to begin the commercial launch in Texas allows the company to hone its message, improve operations, and prepare for a broader market launch.

Industry Context

The announcement highlights the growing market for non-invasive lung cancer diagnostics, with the market projected to reach $4.7 billion by 2030. bioAffinity is positioning itself to capitalize on this trend with its CyPath Lung test.

Comparison to Industry Standards

• The 92% sensitivity and 87% specificity of CyPath Lung are competitive with other diagnostic tests for lung cancer.
• The company's focus on a non-invasive test aligns with the industry trend towards less invasive diagnostic methods.
• The projected market size of $4.7 billion by 2030 indicates a significant opportunity for companies in the lung cancer diagnostics space.
• The company's strategic beta marketing program in Texas is a common approach for launching new medical technologies.

Stakeholder Impact

• Shareholders will likely view the strong sales growth and increased forecast positively.
• Employees may benefit from the company's growth and expansion.
• Customers (physicians and patients) will have access to a non-invasive lung cancer diagnostic test.
• Suppliers may see increased demand for their products and services.

Next Steps

• The company plans a broader market launch for CyPath Lung in the fourth quarter of 2024.
• The company will continue to expand its sales team and onboard new physicians.

Key Dates

Keywords

CyPath Lung, lung cancer, diagnostics, sales growth, biotechnology, noninvasive test, pulmonary nodules, market launch, revenue, sensitivity, specificity